Previous close | 133.86 |
Open | 134.36 |
Bid | 134.23 x 400 |
Ask | 134.33 x 400 |
Day's range | 133.58 - 135.98 |
52-week range | 74.75 - 142.00 |
Volume | |
Avg. volume | 3,054,890 |
Market cap | 51.775B |
Beta (5Y monthly) | 1.21 |
PE ratio (TTM) | 103.31 |
EPS (TTM) | 1.30 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 151.32 |
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
EVP Strategy and Corporate Development Matthew Dolan has sold 1,990 shares of DexCom Inc (NASDAQ:DXCM) on April 15, 2024, according to a recent SEC filing.
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.